Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central anxious process, conolidine modulates alternate molecular targets. A Science Advances review discovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://garrisonp602ytn8.dm-blog.com/profile